A large proportion of the Medicare PD population resides in an LTCF. 2 key findings →
Design: cohort study Participants: 38,334 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Research
27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Older adults with diabetes and dementia are at increased risk for hypoglycemia and other adverse events associated with tight glycemic control and are unlikely to experience long-term benefits. 4 key findings →
Design: cohort study Participants: 15,880 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
(N = 382 at baseline) had a mean (SD) age of 75.5 (7.0) years; 61.8% were women; and 41.4% were white, 29.6% African American, 25.1% Hispanic, and 3.9% other race/ethnicity. 3 key findings →
Design: cohort study Participants: 382 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
At cohort entry, the mean age was 54.8 years (SD 13.3), 56.5% were men, and 72.8% were black. 4 key findings →
Design: cohort study Participants: 324 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
61/100
Although APOE ε4 carriers are at high risk for cognitive decline, our findings suggest possible intervention targets, including the enhancement of cognitive reserve and improvement of other psychosocial and health factors, to promote cognitive resilience among black and white APOE ε4 carriers. 5 key findings →
Design: prospective cohort Participants: 2,487 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
59/100
International hospital-based studies have indicated a high risk of cognitive impairment after stroke, evidence from community-based studies in China is scarce. 2 key findings →
Design: cross-sectional Participants: 599 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The objective of the study was to examine variability across multiple prospective cohort studies in level and rate of cognitive decline by race/ethnicity and years of education. 3 key findings →
Design: cohort study Participants: 4,115 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
59/100
The rate of cognitive change in elderly persons with and without diabetes mellitus is similar, although cognitive performance is poorer in persons with diabetes mellitus. 3 key findings →
Design: cohort study Participants: 1,493 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Incident stroke was associated with an acute decline in cognitive function and also accelerated and persistent cognitive decline over 6 years. 5 key findings →
Participants: 2,003 Evidence: moderate
Full summary, score breakdown and related studies → Original source
58/100
This paper reports findings from a systematic review of the literature on the general public's knowledge and understanding of dementia/Alzheimer's disease. 1 key finding →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Covert cerebrovascular disease and its consequences on cognitive and gait performance and brain atrophy are manifest in some clinically asymptomatic persons as early as the 5th decade of life. 3 key findings →
Participants: 803 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This study shows that a minority of Dutch physicians find it conceivable that they would grant a request for EAS from a patient with psychiatric disease, dementia or a patient who is tired of living. 2 key findings →
Design: cross-sectional Participants: 1,456 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
A cross-sectional study of geriatric patients was performed to provide a comprehensive description of the prevalence and clinical characteristics of chronic itch affecting Hispanic geriatric subjects in Mexico. 1 key finding →
Design: cross-sectional Participants: 302 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Health care aides frequently report care that is rushed and tasks omitted due to lack of time. 4 key findings →
Design: cross-sectional Participants: 583 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The past century was a period of increasing life expectancy throughout the age range. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Previous studies have indicated a prevalence of dementia in older admissions of ∼42% in a single London teaching hospital, and 21% in four Queensland hospitals. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The IDEA cognitive screen performed well in these populations and should prove useful in screening for dementia and delirium in other areas of sub-Saharan Africa. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Accurate assessment of cognitive impairment requires comparison of cognitive performance in individuals to performance in a comparable healthy normative population. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
This review traces evidence that age-related dementia (Alzheimer's disease) results from the destructive impact of the pulse on cerebral vasculature. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Taiwan's accelerated rate of aging is more than twice that of European countries and United States. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →